Michal Fresser
Vorstandsvorsitzender bei AXON Neuroscience SE
Profil
Michal Fresser has worked as the Chief Executive Officer at AXON Neuroscience SE since 2019.
He also currently holds a position as Director at AXON HOLDING SE.
Aktive Positionen von Michal Fresser
| Unternehmen | Position | Beginn |
|---|---|---|
AXON Neuroscience SE
 AXON Neuroscience SE BiotechnologyHealth Technology Part of Istrokapital SE, AXON Neuroscience SE is a Cypriot clinical stage biotech company that specializes in peptide-based vaccines for treating fatal human diseases. The company is based in Larnaca, Cyprus. AXON Neuroscience has the single biggest team in the world dedicated exclusively to tau research in relation to treating Alzheimer's disease, with over 60 scientists and 15 senior scientific leaders. The company's lead vaccine, AADvac1, is the most clinically-advanced tau therapy in development for treating and preventing Alzheimer's disease. AXON Neuroscience has extensive knowledge in producing safe and immunogenic vaccines and well-established scalable technology, which allowed it to move quickly in creating its novel peptide vaccine against COVID-19. The company was founded in 1999 by Michal Novak. Michal Fresser has been the CEO of the company since 2013. | Vorstandsvorsitzender | 01.08.2019 |
AXON HOLDING SE
 AXON HOLDING SE Financial ConglomeratesFinance AXON HOLDING SE engages in holding of investments and provision of financing services to related companies. The company was founded on October 23, 2014 and is headquartered in Larnaca, Cyprus. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
AXON Neuroscience SE
AXON Neuroscience SE BiotechnologyHealth Technology Part of Istrokapital SE, AXON Neuroscience SE is a Cypriot clinical stage biotech company that specializes in peptide-based vaccines for treating fatal human diseases. The company is based in Larnaca, Cyprus. AXON Neuroscience has the single biggest team in the world dedicated exclusively to tau research in relation to treating Alzheimer's disease, with over 60 scientists and 15 senior scientific leaders. The company's lead vaccine, AADvac1, is the most clinically-advanced tau therapy in development for treating and preventing Alzheimer's disease. AXON Neuroscience has extensive knowledge in producing safe and immunogenic vaccines and well-established scalable technology, which allowed it to move quickly in creating its novel peptide vaccine against COVID-19. The company was founded in 1999 by Michal Novak. Michal Fresser has been the CEO of the company since 2013. | Health Technology |
AXON HOLDING SE
AXON HOLDING SE Financial ConglomeratesFinance AXON HOLDING SE engages in holding of investments and provision of financing services to related companies. The company was founded on October 23, 2014 and is headquartered in Larnaca, Cyprus. | Finance |
